The Risks Of Investing In AstraZeneca plc

Royston Wild outlines the perils of stashing your cash in AstraZeneca plc (LON: AZN).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today I am highlighting what you need to know before investing in AstraZeneca (LSE: AZN) (NYSE: AZN.US).

Sales projections to haunt AstraZeneca later on?

In a bid to stave off the overtures of US rival Pfizer, AstraZeneca chief executive Pascal Soriot announced back in May that a rejuvenated research and development plan is set to turbocharge revenues to a mammoth $45bn by 2023.

This was a bold statement given that turnover at the company continues to slide, and group sales rung in at just $25.7bn last year. And as astrazeneca2Barclays Capital points out, around $15bn of this projection is generated from drugs which are yet to pass through the company’s pipeline, a risky strategy given the hit-and-miss nature of drugs testing.

AstraZeneca has already cautioned that its massive restructuring plan — which includes the construction of a brand new state-of-the-art HQ in Cambridge and establishment of several ‘satellite’ bases across Europe and the US — will not make a meaningful contribution to the firm’s revenues until 2018 at the soonest.

In the meantime the business will continue to suffer the effect of crumbling patents, such as that of cholesterol-battler Crestor later this year — this one drug alone is responsible for more than a quarter of group turnover.

Against this backdrop AstraZeneca will need to continue delivering a steady stream of good news from its extensive testing network. The firm received a boost this week when the US Department of Justice closed annexed an investigation into a trial used to gain marketing approval for its Brilinta cardiovascular drug, long identified by the business as a significant sales driver in coming years.

But given the unpredictable and often prolonged process that new products have to pass through, any setbacks could deliver a hammerblow to the company’s earnings prospects.

AstraZeneca is expected to punch a third successive annual earnings dip this year, with a 13% fall currently pencilled in by City brokers. This leaves the pharma giant dealing on a P/E multiple of 16 for 2014, above the benchmark of 15 which is generally considered reasonable value for money. And this moves to 17.1 for next year amid predictions of a further 6% fall.

By comparison GlaxoSmithKline, which in my opinion has a far more bubbly pipeline than its rival, trades on far more attractive multiples of 14.8 and 14 for 2014 and 2015 correspondingly. Given AstraZeneca’s relatively-heady premium, I believe that any signs of spluttering product development could have a catastrophic effect on the firm’s share price.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any shares mentioned. The Motley Fool has recommended shares in GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Passive income text with pin graph chart on business table
Investing Articles

Yields of up to 7%! I’d consider boosting my income with these FTSE dividend stocks

The London market has some decent-looking dividend stocks right now, and I’m tempted by these two for growing income streams.

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

I’d put £20K in an ISA now to target a £1,900 monthly second income in future!

Christopher Ruane shares why he thinks a long-term approach to investing and careful selection of shares could help him build…

Read more »

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »